AT-06 A PHASE II TRIAL OF TAMOXIFEN AND BORTEZOMIB IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA

BACKGROUND: Preclinical studies indicated that inhibition of NF-kB with bortezemib markedly enhance tamoxifen-mediated glioma apoptosis. A potentially synergistic cytotoxic effect of the combination may benefit patients with malignant gliomas. METHODS: We conducted single institution phase II trial...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Aregawi, Dawit, Kreisl, Teri N., Innis, Ellen, Fine, Howard A.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2014
Subjects:
Abstracts
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217841/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items